Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice.
Animals
Antibodies, Neutralizing
/ immunology
Antibodies, Viral
/ immunology
COVID-19
/ immunology
COVID-19 Vaccines
/ administration & dosage
ChAdOx1 nCoV-19
Immunization, Secondary
Immunogenicity, Vaccine
Mice
RNA, Viral
/ administration & dosage
SARS-CoV-2
/ immunology
Spike Glycoprotein, Coronavirus
/ genetics
T-Lymphocytes, Cytotoxic
/ immunology
Th1 Cells
/ immunology
Vaccination
/ methods
Vaccines, Synthetic
/ administration & dosage
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
17 05 2021
17 05 2021
Historique:
received:
28
01
2021
accepted:
19
04
2021
entrez:
18
5
2021
pubmed:
19
5
2021
medline:
29
5
2021
Statut:
epublish
Résumé
Several vaccines have demonstrated efficacy against SARS-CoV-2 mediated disease, yet there is limited data on the immune response induced by heterologous vaccination regimens using alternate vaccine modalities. Here, we present a detailed description of the immune response, in mice, following vaccination with a self-amplifying RNA (saRNA) vaccine and an adenoviral vectored vaccine (ChAdOx1 nCoV-19/AZD1222) against SARS-CoV-2. We demonstrate that antibody responses are higher in two-dose heterologous vaccination regimens than single-dose regimens. Neutralising titres after heterologous prime-boost were at least comparable or higher than the titres measured after homologous prime boost vaccination with viral vectors. Importantly, the cellular immune response after a heterologous regimen is dominated by cytotoxic T cells and Th1
Identifiants
pubmed: 34001897
doi: 10.1038/s41467-021-23173-1
pii: 10.1038/s41467-021-23173-1
pmc: PMC8129084
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
COVID-19 Vaccines
0
RNA, Viral
0
Spike Glycoprotein, Coronavirus
0
Vaccines, Synthetic
0
spike protein, SARS-CoV-2
0
ChAdOx1 nCoV-19
B5S3K2V0G8
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2893Subventions
Organisme : Medical Research Council
ID : MC_PC_19055
Pays : United Kingdom
Références
Nat Med. 2021 Feb;27(2):270-278
pubmed: 33335323
Nature. 2020 Oct;586(7830):578-582
pubmed: 32731258
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
Nat Microbiol. 2020 Oct;5(10):1185-1191
pubmed: 32908214
Cell. 2020 Nov 12;183(4):996-1012.e19
pubmed: 33010815
Biochem Biophys Res Commun. 2014 Aug 22;451(2):208-14
pubmed: 25073113
Nat Med. 2021 Feb;27(2):279-288
pubmed: 33335322
J Infect Dis. 2019 Apr 8;219(8):1187-1197
pubmed: 30407513
ACS Nano. 2020 May 26;14(5):5711-5727
pubmed: 32267667
Clin Exp Immunol. 2020 Nov;202(2):162-192
pubmed: 32935331
Nature. 2020 Oct;586(7830):583-588
pubmed: 32731257
PLoS One. 2012;7(4):e35421
pubmed: 22536382
Lancet. 2021 Dec 19;396(10267):1979-1993
pubmed: 33220855
Med (N Y). 2021 Mar 12;2(3):243-262.e8
pubmed: 33521747
Hum Vaccin Immunother. 2017 Dec 2;13(12):3020-3032
pubmed: 29083948
Mol Ther. 2014 Mar;22(3):668-674
pubmed: 24374965
Lancet Infect Dis. 2020 Jul;20(7):816-826
pubmed: 32325038
NPJ Vaccines. 2020 Jul 27;5:69
pubmed: 32793398
Nat Commun. 2020 Jul 9;11(1):3523
pubmed: 32647131